Biofrontera (BFRI) Receivables (2020 - 2025)

Biofrontera's Receivables history runs 6 years deep, the most recent figure standing at $12.1 million for Q4 2025.

• On a quarterly basis, Receivables rose 13.9% year-over-year to $12.1 million in Q4 2025; TTM through Dec 2025 was $12.1 million, a 13.9% increase from a year earlier, with the FY2025 full-year figure at $12.1 million, up 13.9% from the prior year.
• Receivables improved to $12.1 million in Q4 2025 per BFRI's latest filing, from $3.0 million in the prior quarter.
• Across five years, Receivables topped out at $13.9 million in Q1 2022 and bottomed at $2.1 million in Q3 2021.
• The 5-year median for Receivables is $5.6 million (2022), against an average of $6.5 million.
• Across the five-year window, Receivables surged 271.4% in 2022 and plunged 53.08% in 2024, its largest moves.
• Year by year, Receivables stood at $3.9 million in 2021, then surged by 163.85% to $10.2 million in 2022, then declined by 22.31% to $8.0 million in 2023, then surged by 33.32% to $10.6 million in 2024, then increased by 13.9% to $12.1 million in 2025.
• Per Business Quant, the three latest BFRI Receivables figures stand at $12.1 million (Q4 2025), $3.0 million (Q3 2025), and $4.0 million (Q2 2025).